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Abstract. Background/Aim: MiR-221, often described both as
an oncogenic microRNA and as a tumour suppressor, targets
mRNAs involved in carcinogenesis. While other oncogenic
microRNAs showed correlations with prostate cancer cell lines’
aggressiveness, miR-221 showed an unusual overexpression in
PC3. Materials and Methods: CRISPR was used to delete miR-
221 from PC3 cells. Analysing the characteristics of PC3miR-
221del cells, a reduced growth rate and expression of cell-cycle
genes was observed. In global gene expression/ontology
analysis of PC3miR-221del cells, cell-cell and cell-substrate
adhesion pathways were found to be greatly affected. In
addition, reduced levels of adhesion, invasion and motility for
PC3miR-221del cells, a change in F-actin localisation and a
reduction of EMT markers were observed. Results: The tumour
suppressor gene, DIRAS3, was a predicted target of miR-221.
In PC3miR-221del cells DIRAS3 was up-regulated at the gene
and protein level. Ectopic expression of DIRAS3 in PC3wt cells
recapitulated the cellular morphology changes seen in PC3miR-
221del cells. DIRAS3 3’UTR was more stable in PC3miR-221del
cells, as measured by semi-quantitative PCR and luciferase
fusion reporter assays. Conclusion: MiR-221 promotes
aggressiveness of PC3 cells by down-regulating DIRAS3, and
promoting epithelial-to-mesenchymal transition.
Prostate cancer (PCa) is rapidly becoming one of the most
common malignancies and a leading cause of cancer-
associated mortality in males in the western world (1-3).
MicroRNAs (miRs) are involved in many diseases, including
prostate cancer, and are being developed as predictive and
prognostic markers of disease, or indeed as therapies (4, 5).
miRs are short 20-24 nucleotide non-coding RNAs which are
involved in post-transcriptional regulation of gene expression
by both affecting the stability and translation of mRNAs (6-
8). miRs are transcribed by RNA polymerase II as pri-MiRs,
which are then cleaved by the Drosha ribonuclease into a
shorter 70-bp sequences named pre-microRNAs which are
then further cleaved into mature miRs by the activity of the
Dicer ribonuclease. While miR profiling shows that many
miRs are differentially expressed in PCa tissues versus the
corresponding normal tissues, only a small number of them
have been experimentally determined to be involved in the
development and progression of PCa.
Evidence suggests that miRs have a central role in
controlling basic cell functions as well as several aspects of
carcinogenesis – including migration and invasion. MiR
expression is frequently altered in cancer, implicating them
in the regulation of genes involved in tumour development
and progression. The development of metastasis requires
cells to acquire migratory and invasive capacities with
tumours disseminating cells to distant sites. Migration and
invasion are features shared by undifferentiated tumour cells
showing traits of epithelial–mesenchymal transition (EMT). 
Mir-221 is expressed from a short tandem cluster together
with miR-222 located on chromosome X in both human and
mouse, located in an intergenic region of approximately 727
bases. They are homologous, share a seed sequence, and are
highly conserved across vertebrate species. Mir-221 has been
described as an oncogenic microRNA, overexpressed in
many different cancers of epithelial origins and in other
diseases. Mir-221 overexpression has been reported for
example in glioblastomas (9, 10), thyroid (11), breast (12),
hepatocellular (13, 14) and lung (15, 16) cancers. It can
target several mRNAs many of which have roles in
migration, proliferation, and angiogenesis.
Interestingly the role of miR-221/-222 in PCa, remains
debatable and both up- and down-regulation of miR-221/-222
has been reported, especially in CRPC. It is unclear how miR-
221/-222 are transcriptionally regulated during PCa progression,
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from androgen dependence to castration resistance, and whether
miR-221/-222 act as oncogenes (oncomiRs) or tumour
suppressor miRs. In studies using clinical tissue samples of PCa
compared to either benign, or adjacent tissue, the expression of
miR-221 has been found to be reduced – as listed in Table I (17-
24). Conversely, in clinical studies examining low vs. high
grade prostate cancer, miR-221 expression was higher in
Gleason grade >7 samples (25). In experiments on prostate
cancer cell lines (and xenografts) miR-221 has been found to
be overexpressed or to have oncogenic properties when
overexpressed from oligos/plasmids (Table I, 26-31). 
PCa is initially dependent on androgen for growth and is
sensitive to androgen deprivation therapy (ADT). However,
almost all patients progress to castration-resistant prostate
cancer (CRPC). CRPC remains an incurable disease
through multiple resistance mechanisms to ADT. The
aberrant expression of miRs 221/222 has been correlated
with metastatic CRPC and is inversely correlated with the
expression of the cyclin dependent kinase inhibitor, p27kip1,
in primary prostate cancer (28-30, 32). The androgen
receptor has been shown to repress the expression of miR-
221/222 at the pri-miR level and androgen deprivation
therapy may increase miR-221 levels and promote growth
(33). Since, highly advanced prostate cancer may not
require or depend on AR for growth then the complexity of
miR-221 expression may well be context-dependent.
The apparent discrepancy between cellular and clinical
studies seems to be great, especially in the presence of such
clear data from clinical studies involving other cancer types.
The variability between these studies may be related to
different methodology, molecular heterogeneity and sample
collection, however, it indicates more inherent differences
based on differences in cellular environment e.g. stromal
tissue 3D environment to culture cells on tissue culture
treated plasticware. We were, therefore, very interested in
determining miR-221’s role in prostate cancer, especially as
it seemed to be one of the highest expressed miRs in the PC3
cell line.
Materials and Methods
Cell culture. PC3, VCaP, Du145 cells were maintained in DMEM
medium (Sigma, Dorset, U.K.), while LNCaP cells were maintained
in RPMI medium, all with 10% foetal bovine serum (First Link,
UK), 2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml
streptomycin (Sigma). PNT1A, PZ-HPV7 and CA-HPV-10 cells
were maintained in Keratinocyte Serum Free Medium (Sigma),
supplemented with bovine pituitary extract (0.05 mg/ml) and human
recombinant epidermal growth factor (5 ng/ml, Sigma). HUVEC
cells were maintained in Vascular Cell Basal Medium (Sigma) with
Endothelial Cell Growth Kit-BBE (Life Technologies, Glasgow,
UK). All cells were grown at 37˚C, 5% CO2. All cell lines were
obtained from the ATCC cell bank in 2014, and were stored in
liquid nitrogen in aliquots. Cells were used within 10 passages of
the initial stock.
Invasion assays. Cell invasiveness was assessed using an in vitro
Matrigel invasion assay. In brief, transwell inserts containing 8-μm
pores were placed in a 24-well plate (Nunc, Greiner Bio-One) and
coated with 50μg of Matrigel (BD Biosciences, San Jose, CA,
USA). Subsequently 2×104 cells/insert were added and 1 ml of
medium was added to the bottom of the 24-well plate to sustain any
invaded cells. The plate was incubated for 3 days at 37˚C with 5%
CO2 after which inserts were cleaned to remove any non-invaded
cells, before cells were fixed in 4% formaldehyde (v/v) and stained
with 0.5% crystal violet (w/v). Subsequently, invaded cells were
visualised under the microscope and representative images captured
for analysis.
Adhesion, motility and migration assays. Adhesion assay: Cell
suspensions were plated on either normal cell culture treated plastic
ware or plates coated with fibronectin, collagen I, or Matrigel. Cells
were allowed to adhere for 2-4 h after which the media was washed
off and cells were fixed in buffered formalin for 1 h. Cells were
washed and stained with crystal violet for microscopy or dissolved in
acetic acid (10% v/v) for spectrophotometric absorbance measurement.  
Wound healing assay: Cells were grown in 24-well plates until
they had reached a confluent monolayer. A narrow scratch was
applied across the monolayer using a sterile pipette tip. Cells were
washed and media replaced. Cells were then analysed by
microscopy at hourly intervals (0-8 h) and images captured. Wound
area closure was measured using ImageJ software. 
Motility assay: Cells were plated at 30% density and allowed to
adhere overnight. Cells were then washed in PBS and the medium
was replaced with either normal medium (10%) or starvation
medium (0.5% FCS). Cells were then imaged at time intervals (20
min) using the Evos microscope (Life Technologies). Cell motility
was then measured at intervals, 30 cells per well were followed.  
Migration assay: Cells (500,000) were seeded onto the upper
chamber of an 8 μM ThinCert™ insert (Greiner-Bio One Ltd,
Gloucestershire, UK) in 500 μl of medium with 1% (v/v) FCS. The
lower chamber of the 24 well plate contained 1 ml of 10% FCS
RPMI to create a chemoattractant environment. Cells were left to
migrate for either 4 or 24 h, depending on the cell type. At the
appropriate time point, filters were washed with PBS and placed
onto a fresh 24-well plate. An enzyme free cell dissociation solution
(Millipore, Hertfordshire, U.K.) (350 μl) made with calcein AM
(Life Technologies) (ratio of 1.2 μl: 1 ml) was placed in the lower
chamber of the 24-well plate and left to incubate at 37˚C for one h.
The solution was transferred to a black 96-well plate and
florescence was measured using the Glomax multi-detection system
(Promega Corporation, Madison, WI, USA) at excitation and
emission wavelengths of 495/515 nm.
ECIS assays. The ECIS Z theta system (Applied Biophysics Ltd,
Troy, NJ, USA) was used to evaluate cells’ adhesion, migration and
their ability to form a monolayer with tight junctions, using ECIS
96-well W96E1 microarrays (Thistle Scientific Ltd, Glasgow, UK).
40,000 cells per well were seeded into wells of the array. Live
tracking of cell adhesion was carried out over a range of frequencies
from 1,000 to 64,000 Hz using automated modules for 24 h. All the
experiments were conducted at least three times.
RNA extraction and RT. Total RNA samples were prepared using
Trizol reagent (Sigma) and converted to cDNA using the
GoScript™ Reverse Transcription System (Promega). RNA quality
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was assessed using a Bioanalyser 2100 (Agilent, Santa Clara, CA,
USA). For MicroRNA RT-qPCR, 10 ng of total RNA was reverse
transcribed using the TaqMan™ Advanced miRNA cDNA Synthesis
Kit (Life Technologies). 
Q-PCR. Reactions were performed in triplicate in 96-well optical
plates on an ABI One-Step system (Applied Biosystems,
Warrington, U.K.), consisting of 2 μl cDNA, 7 μl PCR-grade water,
10 μl 2× TaqMan Universal PCR Master Mix (Applied Biosystems),
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Table I. A selection of in vitro and clinical studies on miR-221 expression and function in prostate cancer, with a summary of the miR-221 predicted
function classed as oncomiR or tumour suppressor.
Study                                                                 Medium & Analysis                                      Main                                           Predicted role          Ref
                                                                                    method                                               findings                                            of MiR-221
Normal (n=20), ADPC (n=15)                           Plasma samples                 AIPC and ADPC higher than normal                      Oncomir               (26)
and AIPC (n=8) patients                                     Taqman qPCR                            ADPC higher than AIPC                        Tumour suppressor
Gleason grade <7 vs. >7                                  SYBR green qPCR                          Microrna-221 and 222
(non-agressive vs. agressive) (n=35)                    from tissues                             levels significantly higher                              OncomiR              (25)
                                                                                                                               in aggressive prostate cancer
Benign, BPH, primary and                                  Tissue samples                 Expression of miR-221 is reduced in              Tumour suppressor      (17)
metastatic PCa (n=4 pairs)                              Microarray analysis           aggressive PCa and metastatic deposits.
                                                                                                                               Correlation to Gleason score
Validated in BPH (n=9),                                             qPCR                                  Correlation to recurrence.
PCa (n=12), metastasis (n=8)
CRPC (n=8) vs. hormone                                    Tissue samples                         Significant down-regulation                    Tumour suppressor      (18)
naive PCa (n=54)                                               PCR-based array                                     of miR-221
Or CRPC (n=8) vs.                                                                                               Low expression of miR-221 
normal prostate (n=38)                                                                                             associated with shorter 
                                                                                                                                  progression free interval.
                                                                                                                      MiR-221 did not predict time to CRPC
Cells – PC3 and Du145                                        Cell samples                     No inhibition of cell proliferation, 
                                                                             MiR-221 mimic                 effects on inhibiting cell migration,
                                                                              overexpression                      invasion significantly inhibited, 
                                                                                                                                   no change in apoptosis.
Radical prostatectomy (n=153)                           Tissue samples               MiR-221 is down-regulated in patients           Tumour suppressor      (19)
                                                                           SYBR green qPCR                    with TMPRSS2:ERG fusion. 
                                                                                                                            Down-regulated with metastasis.
2 cohorts A: (n=134), B: (n=89)                  Taqman qPCR on RNA            Down-regulated in PCa compared
                                                                              extracted from                      to BPH. Independent predictor
                                                                    paraffin-embedded tissues.                        for cancer death.
Cells: PC3, Du145 and LNCaP                       Mir221 transfection           PC3/Du145 down-regulation of growth,           Tumour suppressor      (20)
                                                                                                                                    LNCaP up-regulation
                                                                                                                        Reduced invasion, reduced apoptosis
Cells: PC3                                                                    qPCR                                PC3 express high miR-221                              Oncomir               (27)
                                                                            Transfections and                            compared to LNCaP
                                                                                   reporters                       MiR-221 Inhibition showed reduced 
                                                                                                                                 proliferation & migration.
                                                                                                                                       Increased apoptosis
Cells: LNCaP and LNCaP-AI                              Taqman qPCR                      Up-regulation of miR-221 in AI                          Oncomir            (29, 30)
                                                                                                                       Overexpression of miR-221 – reduced
                                                                                                                      AR transcription, pro CRPC phenotype
Cells: LNCaP tumours                                     Tissue and cell lines                Ectopic overexpression miR-221                         Oncomir               (31)
                                                                                                                    confers high growth advantage to LNCaP
                                                                                                                   Inhibition in PC3 – reduces tumour growth
Patients: stage II-III (n=21) primary                   Taqman qPCR                           Up-regulation in patients 
samples taken for cell culture.                                                                                      derived cell lines.
BPH (n=4) PCa (n=9)                                Tissue, cell lines, xenografts                MiR-221 down-regulated                       Tumour suppressor      (21)
Cell lines (n=6), xenografts (n=9)                   SYBR green qPCR                              in all carcinomas
Pooled PCa samples vs. normal (n=5)                       Tissues                                 MiR-221 down-regulated                       Tumour suppressor      (22)
                                                                            Deep sequencing 
Primary (n=60) and                                                    Tissues                                 MiR-221 down-regulated                       Tumour suppressor      (23)
Non-tumour (n=16)                                                     qPCR
PCa samples (n=20)                                         miRNA microarrays                      MiR-221 down-regulated                       Tumour suppressor      (24)
                                                                                   & qPCR
1 μl Taqman specific assay probes (Applied Biosystems) for
DIRAS3, RPL19, β-actin, and GAPDH. Parameters were: 50˚C for
2 min, 95˚C for 10 min, 40 cycles of 95˚C for 15 sec and 60˚C for
1 min. Data was recorded using Sequence Detector Software
(Applied Biosystems) and normalised to GAPDH, β-actin and
RPL19.
MicroRNA-seq analysis. Total RNA was isolated from PC3 cells
using the mirVana miRNA Isolation Kit (Thermofisher, Waltham,
MA, U.S.A.), following a protocol to enrich for small RNAs <200
bp. This was verified using a Bioanalyser-2100 (Agilent). RNA
fragment libraries (150-200 bp) were generated using the Nextflex
Small RNA sequencing kit (Perkin Elmer, Waltham, MA, USA) and
ligated to adapters for cDNA synthesis. cDNA was then amplified
using barcoded primers (5’) and quantified with a Qubit assay (Life
Technologies).
cDNA libraries were clonally amplified by emulsion PCR on Ion
Sphere Particles (ISP’s) using Ion PI template OT2 200 kit (Life
Technologies) on an Ion OneTouch2 system (Life Technologies) as
per manufacturer’s instructions. The template positive ISP’s were
recovered and enriched to remove non-template ISP’s on Ion One
Touch ES (Life Technologies). The ISPs were processed using the
Ion Proton 200 sequencing kit and loaded onto a P1 chip and
sequenced on an Ion Proton (Life Technologies) using default
parameters (single-end, forward sequencing). Base calling, adaptor
trimming, barcode deconvolution and alignment was performed on
Torrent Suite version 3.6 (Life Technologies) using the STAR RNA-
seq aligner plugin. The Partek Genomic Suite 6.6 software was used
for data analysis. 
Ampliseq (RNA-seq). Total RNA was isolated from cells using
Trizol (Sigma) and DNase treated before use. The IonAmpliseq™
Transcriptome Human Gene Expression kit (Life Technologies) was
used for reverse transcription to cDNA. The Human Gene
Expression Core Panel primer set (Life Technologies) was then used
to prepare small amplicon gene expression libraries targeting 20,000
genes (95% of the RefSeq gene database). Protocols were followed
according to manufacturer’s protocols.
The cDNA amplicon libraries (125-300 bp) were ligated to
adapters and amplified using IonXpress RNA-seq barcoded primers
(5’). cDNA libraries were clonally amplified using Ion PI template
OT2 200 kit (Life Technologies, USA) on an Ion OneTouch2 system
(Life Technologies) as per manufacturer’s instructions. Samples
were processed using the Ion Proton 200 sequencing kit and loaded
onto a P1 chip and sequenced on an Ion Proton (Life Technologies)
using default parameters (single-end, forward sequencing). Base
calling, adaptor trimming, barcode deconvolution, alignment and
Ampliseq gene expression analysis was performed on Torrent Suite
version 3.6 (Life Technologies) using the STAR RNA-seq aligner
plugin. 
Donor plasmid generation. The homologous recombination plasmid
(pHR110PA-1) was obtained from Cambridge Bioscience,
Cambridge, UK. The genomic regions representing 1 kb
downstream and 1 kb upstream of the mir-221 genomic locus
(representing the mature miRNA coding region) were amplified by
PCR and ligated into the pHR110PA-1 plasmid sequentially i, right
homology arm into BamH1/Sph1 sites and then ii, left homology
arm into the EcoR1/BglII sites. Left homology arms primers 5’-
[GAGCTC]CCATTATTACATGTAGACATTTATC-3’ and 5’-[AGA
TCT]GCTACCTGGAAACATGTTCT-3’ and right homology arm
primers 5’-[GGATCC]ATGTTCAGCTTGCAAGTAATTCT-3’ and
5’-[GCATGC]CCAGAAGGCAAAGGATCA-3’. This generated the
pHR110PA-1 miR221-HDR plasmid. Sequences were verified by
sequencing and restriction mapping.
gRNA plasmid generation. The pSpCas9(BB)-2A-GFP (PX458)
plasmid was a gift from Feng Zhang (Addgene plasmid # 48138).
Several gRNA plasmids targeting potential sites across the mir-221
region were generated. Briefly the guide sequence oligos were
designed using CRISPR gRNA design tool (Life Technologies) and
synthesized from MWG-Eurofin Ltd, Ebersberg, Germany. These
were annealed and ligated into the sgRNA scaffold at the Bbs1 site
using the following structure 5’-CACCG(N)19-3’ and 5’-
AAAC(N)19C-3’. 
Transfection. PC3 cells were transfected with pHR110PA-1 miR221
and gRNA (pX458) simultaneously and allowed to grow for 24 h,
after which they were treated with 1ug/ml puromycin. Cells were
then plated out and diluted on a 96-well plate as single cells/well,
and individual colonies were isolated and expanded. Plasmid
integration and recombination events were validated by genomic
PCR and fluorescence microscopy, with 100% of cells showing RFP
fluorescence in the expanded cell lines. Mir-221 expression was
then analysed by Q-PCR. Individual miR-221 knockout clones were
then recombined as a multi clonal mixed cell line.  
Generation of a DIRAS3 mammalian expression vector. The full-
length coding region of DIRAS3 was amplified from PC3 cDNA
using the primers: For 5’-ATGGGTAACGCCAGCTTTGG-3’ and
Rev 5’-TCACATGATTATGCACTTGTCAAGCA-3’. The PCR
amplification product was ligated into pEF6-TOPO vector (Life
Technologies), and confirmed by sequencing and directional PCR.
The plasmids were transfected into PC3 cells with Lipofectamine
3000 (Life Technologies).
Generation of a DIRAS3 3’UTR luciferase reporter & activity
assays. The 3’UTR sequence of DIRAS3 (645 bp) containing the
miR221/222 sites was PCR amplified from PC3 cDNA using the
primers: For 5’-[GAGCTC]GCCCTGGGCCTTAAGAGC-3’ and
Rev 5’-[GTCGAC]TGCATGCAGGAAAAGCTTTATTAAGTC-3’.
The PCR product was digested with Sac1 and Sal1 and ligated into
the pMiR-Glo vector (Promega). 
The plasmids were transfected into PC3 cells with Lipofectamine
3000 (Life Technologies) and luciferase assays carried out 24 h later
using the Stop and Glo assay kit for firefly and renilla luciferase
(Promega). Luciferase activity was normalised to renilla activity.
Results
Analysis of the microRNA expression profile of the PC3
prostate cancer cell line. PC3 cells represent highly
aggressive prostate cancer. The cell line grows rapidly in
culture and in vivo xenografts, where it spontaneously forms
metastatic lesions. Additionally, the cell line does not express
androgen receptor and is completely androgen independent.
PC3 cells are also negative for several luminal differentiation
markers, and show some (but not all) similarities with small
cell neuroendocrine carcinomas (SCNC) (34). Total RNA
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5314
Dart et al: Mir-221 Deletion in PC3 Cells
5315
Figure 1. MiR-221 is the second highest expressed miR in PC3 cells. A) MiR-Seq analysis of miR expression from PC3 cells – graph shows the top
20 highest expressed miRs. Data is given as reads per million. B) Table showing the characteristics of the prostate cell line panel used in this study.
Cell lines have been ordered according to apparent aggressive tendency (by our own parameters as indicated). C) Q-PCR analysis of miRs 221,
16, 125a and 27a expression in a panel of prostate cell lines, ranked according to the characteristics in the Table. Data is normalised to U6 and
U8 small nuclear RNAs and then normalised to HUVEC cells. Graphs represent three independent replicates. 
was isolated from PC3wt cells and was subjected to RNA
size fractionation to isolate <200 bp RNA species. The miRs
were then sequenced using the NextFlex miR sequencing kit.
The total miR expression of PC3 was analysed and
normalized using Partek Genomics Suite. Analysis of miR
expression content indicated that hsa-miR-221-3p was the
second most strongly expressed miR in PC3 cells (Figure
1A), after hsa-miR-16-5p.
Various studies have indicated that miR-221 functions
both as an oncogene and a tumour suppressor. Additionally,
in clinical samples miR-221 has been found to be lost or
down-regulated, and in vitro studies have shown that miR-
221 is correlated with increased growth and invasiveness and
with the development of androgen independence. Table I
presents a sample of clinical and in vitro studies which show
the apparent disparity in relation to miR-221. Such in vitro
studies have classically been carried out with exogenous miR
mimics or inhibitors and as such represent an artificial
system where oligonucleotide manipulation may promote
other off target effects. Here, we have investigated the
genetic deletion of the mature miR-221 nucleotide from the
genome using CRISPR technology.  
Analysis of miR expression across a panel of prostate cancer
cell lines. MiR-221 expression was analysed in a panel of
prostate cell lines. We utilized human HUVEC cells (Human
Umbilical Vein Endothelial Cells) as a control for normal non-
immortalised human cells to give a baseline for miR
expression/comparison. Additionally, mouse normal prostate
tissue was used since fresh human normal prostate tissue was
unavailable. Cells and tissues were ranked in order of
aggressiveness according to our own criteria - comparing tissue
derivation, immortalization, tumourigenicity and metastatic
potential in nude mice (Figure 1B). The oncomiRs mir-27a,
miR-155 and miR-16 were found to have a strong correlation
with aggressiveness across our panel, whereas miR-221 only
showed a high expression level in PC3 cells (Figure 1C). 
Generation of a miR-221 knock out cell line. As miR-221
was one of the most abundant miRs expressed in PC3 cells
and was much higher in PC3 than other cell lines, we
decided to use a CRISPR/Cas9 system to delete/ remove the
miR-221 genomic sequence from chromosome X of PC3
cells. PC3 cells were transfected with the pHR110PA-1
miR221-HDR plasmid and the pX458 targeting plasmid
(gRNA and CRISPR) (Figure 2A). Cells were grown with
puromycin selection and RFP+ve PC3 cells were isolated and
expanded. Genomic recombination events were verified by
genomic DNA extraction and PCR (Figure 2B), and RFP
expression was seen in all cells to some degree (Figure 2C).
The levels of miR-221 became undetectable when assayed
by qPCR analysis (<1%) (Figure 2D). The co-expressed
miR-222 was also greatly reduced down to <16%.
Henceforth the parental PC3 cell line will be called PC3wt
and the CRISPR knock out labelled PC3miR-221del.
MiR-221 knock out decreases cell growth. To ascertain the
effects of miR-221 knock out on PC3 cell growth and
functional characteristics several parameters were assessed.
Firstly, using an MTT assay for cell growth, we noticed that
the growth rate of PC3miR-221del cells was slightly reduced
(Figure 3A). Additionally, when equal number of cells were
grown over 6 days and collected daily for FACS analysis,
PC3wt cells were found to grow faster and reached
confluency sooner, whereas the number of cycling cells was
higher in PC3miR-221del cells, which did not yet reach
confluency (Figure 3B and C). When analysing cell cycle
specific genes in cells grown during the normal growth
phase, the DNA replication genes, MCM3-10 genes, were
expressed less in PC3miR-221del, and the cell cycle dependent
kinase inhibitor genes CDKN1A and CDK2A were up-
regulated (Figure 3D) compared to PC3wt cells.
MiR-221 knock out reduces motility and invasion of PC3
cells. We analysed the phenotypic characteristics of the
PC3miR-221del cells compared to the PC3wt cells in several
assays. Migration of cells was assessed using a transwell
migration assay. PC3miR-221del cells showed less migration
than the PC3wt cells (Figure 4A). Additionally, PC3miR-221del
cells showed less invasive potential in a similar transwell
invasion assay through a matrigel layer (Figure 4B). 
We monitored the random directional motility of PC3 cells
under normal growth conditions in 10% serum and in
reduced serum (<0.5%). In reduced serum neither the PC3wt
nor PC3miR-221del cells showed any significant movement,
but with added serum, PC3wt cells showed a statistically
significant increase in movement distance as expected.
However, no significant increase in motility was seen in the
PC3miR-221del cells (Figure 4C).
We then measured migration and rate of adhesion to form
a monolayer using the Electric cell-substrate impedance
sensing system (ECIS). As cells adhered and formed a
monolayer over 5 h (approx.) the electrical impedance
increase was measured. PC3miR-221del cells showed a
statistically lower electrical resistance, initially, for the first 1-
2 h and then showed no real difference after 4 h (Figure 4D).
We monitored the cell migration and cell–cell interaction
by the scratch/wound healing assay. Over 8-10 h the PC3wt
cells closed the wound completely, whereas the PC3miR-
221del cells had not. The PC3miR-221del cells showed a
delayed wound closure, as after a lag of 2-3 h the velocity
of wound closure was the same as for the parental cell line
(Figure 4E and F).
Mir-221 knock out reduces the rate of cell adhesion. We
analysed the rate of adhesion of the cells to a cell culture
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vessel. Cells from a suspension were allowed to adhere onto
the surface for 2 h, after which cells were washed with PBS
and fixed in formaldehyde solution. Plates were either non-
coated, or coated with fibronectin or matrigel. Cells were then
stained using crystal violet solution and visualized under a
microscope, and counted (Figure 5A). On standard tissue
culture plastic dishes, or on fibronectin or Matrigel, PC3miR-
221del cells showed a reduced number of adhered cells in this
time (Figure 5A). The cells also showed a phenotypic
morphological change in shape, being more rounded and
larger in appearance. Cells appeared less adherent and less
well spread out on the surface. In many cells there was an
absence of a prominent leading lamellopodia or trailing edge
(see figure 5A and B). We then stained the cells with FITC-
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Figure 2. Genomic deletion of miR-221 from PC3 cells using CRISPR and homologous recombination. A) Schematic diagram of the miR-221/222
locus on chromosome X, including the recombination vector designed with 1kb homology arms upstream (Left arm) and downstream (Right arm)
and the CRISPR DNA cleavage gRNA. After strand cleavage DNA homology repair is guided by the donor plasmid which inserts loxP sites, RFP
and puromycin selection. After homologous recombination the RFP and puromycin markers are removed via Cre recombinase. B) Upper panel -
schematic of predicted PCR amplification fragments following genomic recombination events. Lower panel - gel PCR of the homologous
recombination events in PC3wt and PC3miR-221del genomic DNA. C) Phase contrast and fluorescence microscopy of clonal PC3miR-221del cells
showing RFP expression in all cells. D) Q-PCR analysis for miR expression from PC3wt and PC3miR-221del cells. Data represents the mean of three
independent replicates, and is normalised to U6 & U8 small nuclear RNAs. Data is also normalised to PC3 expression. 
conjugated phalloidin to visualize cellular F-actin localisation.
In the larger rounded cells, F-actin was seen to localise in the
periphery of the cytoplasm (Figure 5B). Conversely, PC3miR-
221del cells showed an increase adhesion to collagen coated
dishes (Figure 5A), but this did not translate into increased
invasiveness through the collagen. PC3miR-221del cells showed
very poor adhesion to glass slides, even after 24-48 h.
Mir-221 deletion affects genes involved in cell-cell adhesion
in PC3 cells. We then went on to verify if miR-221 knock out
affected proteins involved in cell adhesion, motility and cell-
cell binding. A simplified schematic diagram of genes
involved in the epithelial–mesenchymal transition (EMT) are
given in Figure 6A. Protein levels were determined using
western blotting. We analysed proteins with known roles in
cellular adhesion either cell-cell adhesion e.g. tight junction
proteins or cell-substrate adhesion e.g. focal adhesions. E-
cadherin, Occludin, ZO-1 and JamB protein levels were up-
regulated in PC3miR-221del whereas vimentin, nectin3, were
down-regulated. MMP1 showed up-regulation in PC3miR-
221del (Figure 6B). Eplin and Rock2 were seen to be up-
regulated, whereas no change was seen in FAK and MMP9
(Figure 6B).
PC3miR-221del cells show changes in gene expression. Since
miRs regulate expression of mRNAs in cells via influencing
strand stability, we utilised an Ampliseq methodology for
gene expression analysis. The deletion of miR-221 resulted
in a change of expression of over 1000 genes [approx. 646
significantly down-regulated genes and 534 up-regulated
genes (–/+ 2-fold change, p=0.05)]. When analysed via IPA
Ingenuity software the main pathways affected by these gene
changes were associated with adhesion, cell-cell binding,
trans-endothelial migration and mobilization of calcium.
These pathways agreed well with the observed changes in
the adhesion observed (Table II). However, no specific
global correlations could be made between gene expression
and miR-221 predicted targets (data not shown).
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Figure 3. MiR-221 deletion reduces cell cycle kinetics and cellular replication. A) Bar graph indicating cell growth and viability of PC3wt and
PC3miR-221del cell over 5 days, as measured by the MTT cell viability assay. B) Graph indicating % of cells in S phase as measured by FACS analysis
for cell cycle distribution. PC3wt and PC3miR-221del cell were grown for six days. C) Cell-cycle distribution histograms of PC3wt and PC3miR-221del
cells at day 6 of growth. X axis represents propidium iodide fluorescence units. D) Q-PCR analysis of various cell cycle regulators and DNA
replication genes in PC3wt and PC3miR-221delcells. Data normalised to GAPDH, β-actin and RPL19.
The DIRAS3 tumour suppressor is a target of miR-221/222.
From the IPA analysis, the main predicted upstream target of
mir-221 was DIRAS3 (ARH1) (Table III). DIRAS3 is a
tumour suppressor gene that is frequently down-regulated in
cancer. It is also a target of miR-222, therefore represents an
interesting target molecule. When we analysed DIRAS3
expression levels in PC3miR-221del cells we saw an almost
10-fold increased expression at the mRNA level when
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Figure 4. MiR-221 deletion reduces migration, motility, invasion and adhesion of PC3 cells. A) Bar graph indicating the number of PC3wt and PC3miR-
221del cells migrated across a membrane in 24 h. B) Bar graph indicating the number of PC3wt and PC3miR-221del cells invading through a matrigel
layer and migrating across a membrane. C) Boxplot indicating the motility of PC3wt and PC3miR-221del cells, in either starvation medium (0.05% FCS)
or full medium (10% FCS) for 8 h. D) Graph indicating the resistance and electrical impedance of PC3wt and PC3miR-221del cells adhering to the ECIS
assay plate over 5 h. Boxplot (inset) represents the resistance as measured at 1.5 h. E) Boxplot representing the % closure of a scratch (wound healing)
assay of PC3wt and PC3miR-221del cells over 8 h. F) Grayscale photograph of the PC3 cells at the 8 h time index. * p=0.05, ** p=0.01.
compared to PC3wt cells, or any other prostate cell line in
our panel (Figure 7A). DIRAS3 protein levels were also
increased in these cells, as shown by western blotting (Figure
7B). DIRAS3 full length transcript (1.3kb coding and 3’UTR
combined) was also increased in the PC3miR-221del cells as
compared to the PC3wt- as analysed by semi-quantitative
PCR (Figure 7C).
We cloned the coding sequence of the DIRAS3 cDNA into
pEF6-TOPO (Invitrogen) for mammalian cell ectopic
expression. When we overexpressed this protein in PC3wt
cells (Figure 7D) we found that in a wound healing assay
these cells showed very retarded movement and failure to
close the wound entirely (Figure 7E). Additionally, DIRAS3
expressing cells became rounded and less adherent, and
when stained with phalloidin for F-actin showed the same
ring-like structure of F-actin fibres. Cells also showed no
leading lamellipodia and cytoplasmic ruffling, as was
previously indicative in the PC3miR-221del cells (Figure 7F).
Additionally, upon ECIS analysis, DIRAS3 overexpression
reduced the ability of the PC3wt cells to produce a mature
cell monolayer, with any electrical resistance (Figure 7G).
After a wound was applied (via an electric field) the PC3wt
cells overexpressing DIRAS3 failed to reproduce a
monolayer with any electrical resistance (Figure 7H).
We then analysed the stability of the DIRAS3 UTR
sequence in PC3wt and PC3miR-221del cells. We fused the
3’UTR sequence of DIRAS3 into the firefly luciferase of the
pMirGlo reporter (Promega) (Figure 6). When transiently
ANTICANCER RESEARCH 39: 5311-5327 (2019)
5320
Figure 5. MiR-221 deletion affects cell adhesion and morphology. A) Photograph of PC3wt and PC3miR-221del cells allowed to adhere for 2 h on
cell culture plastic dishes. Upper panel x10, lower panel x40 magnification. Boxplot (left) indicates the number of cells adhered to each type of
coated surface after 2 h as measured by counting crystal violet stained cells. B) F-actin (Phalloidin-FITC conjugate) staining of PC3wt and PC3miR-
221del cells after adhesion to cell culture plastic for 4 h.  
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Figure 6. MiR-221 deletion alters components of the epithelial to mesenchymal transition (EMT) in PC3 cells. A) Schematic indicating the genes
involved cell-cell adhesion, cell-surface adhesion and how they change during the EMT in cancer. B) Western blotting for various components of
the EMT in PC3 wt and PC3miR-221del cells. Equal loading was verified by probing for GAPDH. 
transfected into PC3wt or PC3miR-221del cells the stability and
activity of the luciferase reporter was increased in the PC3miR-
221del cells. The DIRAS3 UTR showed a lower activity in both
cell lines when compared to the empty vector (Figure 7I).  
Discussion
MicroRNAs and non-coding RNAs modulate the
transcriptome and have been found to be increasingly
important regulators of several physiological and disease
states. Mir-221 is described as an oncogenic microRNA. It can
target several mRNAs, many of which have roles in migration,
proliferation, and angiogenesis. However, its exact role and its
effects on disease outcome or progression is under some
debate. There appears to be a discrepancy between the
observed in vitro effects of miR-221 on cancer cells and the
clinical outcomes or risk factors for patients with cancer. 
Other oncogenic miRs, e.g. miR-16 and 27a, were
proportionally up-regulated with increased aggressiveness of
the cell line, but miR-221 was seen to be very highly
expressed in PC3 when compared to other prostate cell lines
– being the second most highly expressed cellular miR.
However, the less aggressive benign tissue-derived cell lines,
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Table II. Functional annotation results from the Ingenuity Pathway Analysis (IPA) software on the gene expression changes seen in PC3miR-221del
cells, as detected by Ampliseq. 
Category                                                                                                                                                Functions annotation                                    p-Value
Cardiovascular System Development, Cell-to-cell signaling and interaction                     Adhesion of vascular endothelial cells                        0.001
Cell-to-cell signaling and interaction                                                                                      Binding of prostate cancer cell lines                          0.003
Cell-to-cell signaling and interaction                                                                                    Adhesion of prostate cancer cell lines                        0.005
Cellular movement                                                                                                   Trans-endothelial migration of prostate cancer cell lines         0.016
Cell signaling, molecular transport, mineral metabolism                                                                  Mobilization of Ca2+                                      0.026
Table III. Top networks and diseases affected predicted from the Ingenuity Pathway Analysis (IPA) software on the gene expression changes seen in
PC3miR-221del cells, as detected by Ampliseq.
Molecules in network                                  Score                                                             Top diseases and functions
DMD,ESR2,HMGA1,IER2,JUN,JUNB,
MAPK9,NR3C2,PTGS2,TGFB1,TNF           9                       Endocrine System Disorders, Gastrointestinal Disease, Inflammatory Disease
CHUK, CXCL12, CXCR4, RELA                 3           Cell-To-Cell Signalling and Interaction, Cell Morphology, Cell-mediated Immune Response
GSK3B, SH3GLB1                                         1                        Cell Morphology, Cellular Function and Maintenance, Neurological Disease
BCL2, PTEN                                                   1                                                 Tissue Morphology, Cell Morphology, Cancer
CEBPB, HIPK2                                               1       Cell-To-Cell Signalling and Interaction, Cellular Assembly and Organization, Cellular Compromise
DIRAS3, mir-221                                            1                                        Cellular Development, Cellular Growth and Proliferation
BMP6, DKK1                                                  1                         Cellular Development, Embryonic Development, Organismal Development
CFLAR, FOS                                                   1                       Cell Death and Survival, Nervous System Development and Function, Cancer
AGR2, CBX1, CDKN2A                                1                                 Cancer, Cellular Development, Cellular Growth and Proliferation
BGLAP, PLAU, PREX1, SP3                        1       Digestive System Development and Function, Embryonic Development, Organismal Development
DDIT3, RHOC, TNFRSF10B, UACA           1        Cell Death and Survival, Digestive System Development and Function, Gastrointestinal Disease
→
Figure 7. DIRAS3 is a target of MiR-221 and is more strongly expressed
in PC3miR-221del cells. A) Q-PCR analysis of DIRAS3 expression in a
panel of prostate cell lines. Expression was normalised to GAPDH, β-
actin and RPL19. B) Western blot showing expression of DIRAS3 in
PC3wt and PC3miR-221del cells. GAPDH was probed on the same
membrane as a control. C) Semi-quantitative PCR of DIRAS3-UTR
(coding and UTR - 1.3 kb) and GAPDH (500 bp). DIRAS3-UTR required
32 cycles, GAPDH required 24 cycles. D) Bar graph indicating the
expression levels of DIRAS3 in PC3wt cells transfected with pEF6-
DIRAS3 to ectopically overexpress DIRAS3. E) Boxplot representing the
% closure of a scratch (wound healing) assay of PC3wt cells either
untreated, mock treated, transfected with either empty pEF6 or pEF6-
DIRAS3 cDNA, over 8 h. F) Photograph of PC3 cells either transfected
with pEF6-Empty or pEF6-DIRAS3 cDNA for 24 h and stained for F-
actin (Phalloidin-FITC conjugate) and nuclear DNA (DAPI) staining.
Upper panel represents phase contrast microscopic image. Lower panel
represents fluorescent channel imaging (merge). G) Graph indicating the
electrical resistance of PC3wt cells transfected with pEF6-DIRAS3 (or
empty) adhering to the ECIS assay plate over 16 h. H) Recovery of the
electrical resistance of PC3wt cell (transfected with pEF6-DIRAS3 or
empty) of 20 h after the application of an electrical wounding at time=0.
I) Schematic diagram of the empty luciferase reporter (pmiR-Glo) and
the luciferase fused to DIRAS3 3’UTR (left panel) and luciferase activity
from extracts of PC3wt and PC3miR-221del cells transfected with either
pmiR-Glo Empty or pmiR-Glo-DIRAS3 3’UTR reporter plasmids for 
24 h (right side). Data represents firefly luciferase activity over renilla
luciferase (constitutive) activity expressed from the same plasmid. 
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e.g. PNT1A, PZ-HPV7, and low-grade prostate cancer-derived
CA-HPV-10, did show increased miR-221 expression as
compared to the highly aggressive late-stage representative
cell lines LNCaP, VCaP and Du145. This may in part explain
why the in vitro and clinical data on miR-221 are not in
agreement, as this particular miR did not correlate with
aggressiveness across our cell line panel and was mostly
unique to PC3. PC3 cells themselves have been singled out as
potentially being a sub-category of prostate cancer and share
some characteristics of prostatic small cell neuroendocrine
carcinoma (SCNC), but this is still under some debate. 
Therefore, we set out to determine the role of miR-221,
which was very highly expressed in the androgen
independent and aggressive cell line PC3. Rather than using
modified artificially transfected oligos to modulate the levels
and activity of miRs which may generate off-target effects
e.g. RNA oligos can be potent inducers of interferons (IFNs)
and inflammatory cytokines in vitro. Therefore, we decided
to utilise a CRISPR/Cas9 method to delete the bases
encoding for miR-221, according to the methods set out by
Ho et al. (35), Chang et al. (36) and Zhao et al. (37). Cas9
alone may incorporate double strand breaks and small indels
in the genome, which may not be sufficient to knockout the
entire function of a microRNA. Therefore, we utilised an
additional homology recombination-based selection system
by designing a donor vector where the target mir-221 bases
were replaced by RFP and puromycin resistance genes.
Normal male cells would have only 1 copy of the X
chromosome upon which miR-221 is located. However,
since PC3 cells are near-triploid with a modal number of 62
chromosomes (38), we were surprised by the efficiency of
the CRISPR procedure to remove mir-221 to almost
undetectable levels. We cannot rule out that additional copies
of the X chromosome region that may have remained
unmodified or with indels, but the novel genomic
recombination of plasmid DNA was confirmed by PCR.
Indels may not be detected by qPCR methods utilising a
sequence-specific probe. Additionally, we cannot rule out the
global effects of mir-221 knock-out on other miRs, but the
levels of the strongly expressed miR-16 did not change
significantly when analysed by qPCR.
Ampliseq analysis of global gene expression changes of
over 20,000 genes in response to miR-221 knock-out resulted
in 646 significantly down-regulated genes and 534 up-
regulated genes (–/+ 2-fold change, p=0.05). No significant
correlation could be deduced between the down-regulated
genes and miR-221 validated targets – as analysed by
microrna.org, mirDB, Targetscan and Targetminer websites.
Although it should be noted that Ampliseq does not measure
3’UTR regions and their stability. This would indicate that
changing this microRNA may have significant global effects
in the cell. Pathway analysis (IPA) revealed that cell-cell
adhesion and migration were the most affected pathways. 
The cell cycle regulatory pathways did not score highly as
being relevant. The effect of miR-221 on cell growth was
first examined as miR-221 had been reported to target
CDKN1B/p27. The growth of PC3miR-221del cells was slower
than wild type cells, and the % of cells remaining in S phase
was greater after 7 days of growth, indicating they had not
yet reached confluence and contact inhibition. We then
analysed the gene expression of various cell cycle genes e.g.
p21, p27 and the MCM family. There was a significant
reduction of replication related genes e.g. MCM5 and an
increase in the cell-cycle inhibitor genes p21 and p27 – thus,
agreeing with the literature. However, the effects on p27
were not as significant as for p21. 
The main characteristic differences in the PC3miR-221del
cell line was in their adhesion and motility. The deletion of
miR-221 reduced adhesion, motility and invasion in our
assays. In the wound healing assay, there appeared to be a
delay in wound closure of around 2 h, but after which wound
closure velocity appeared the same as the parental cells. The
ECIS assays also showed a delayed production of a viable
monolayer. This would indicate that when cell-cell contact
inhibition was removed i.e. a wound, there was a delay in
either - the detection of, or response to - a loss of cell-cell
contact inhibition. Upon western blotting for markers of
EMT and adhesion, the intermediate filament protein
vimentin was strongly down-regulated. Vimentin contributes
to EMT by mediating cytoskeletal organisation and is
associated with cancer invasion and poor prognosis in
several cancer types including breast and prostate (39, 40).
Previously, Stinson et al. have shown that overexpression of
miR-221 in breast cancer cells could decrease epithelial-
specific genes and increase the expression of mesenchymal-
specific genes (41, 42) e.g. E-cadherin and vimentin
respectively. Eplin-α, a gene found frequently lost during
EMT (43, 44), was up-regulated in PC3miR-221del cells. 
One of the main genes predicted to be affected and to affect
downstream gene expression was the DIRAS3 tumour
suppressor. DIRAS3 is a GTPase belonging to the Ras
superfamily and shares 50-60% homology with Ras and Rap,
two other small GTP binding proteins, whose expression is
reported to be reduced in 70% of invasive breast cancers (45,
46) and 60% of ovarian cancers (47-49). DIRAS3 expression
was markedly increased in PC3miR-221del cells at gene and
protein levels. Ectopic overexpression of DIRAS3 cDNA in
PC3wt cells greatly reduced their ability to close a wound in
the wound healing assay (& ECIS), and cells became rounded
up and detached from the substrate forming large rounded
cells with F-actin fibres, similar to those seen in PC3miR-221del
cells. This would indicate a phenotypic mirroring of miR-221
loss and DIRAS3 expression. Additionally, the full-length
mRNA (coding and UTR) expression was increased in
PC3miR-221del cells and the luciferase-fused construct showed
an increased activity in the PC3miR-221del cells; this would
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indicate that DIRAS3 is indeed a target of mir-221 (&miR-
222). An inverse correlation between low DIRAS3 and high
miR-221/222 levels has been shown in prostate cancer tissues,
with a more aggressive tendency (25). DIRAS3 has important
roles in inhibiting cell proliferation and migration whilst
promoting apoptosis. It can also promote autophagy and
induce tumour dormancy (50). The cellular morphology
changes in PC3 cells by DIRAS3 overexpression and the
inhibition of invasion have been previously demonstrated (51). 
Conclusion
The role of miR-221 in PCa has shown stark differences to
that observed in other types of cancer, with an apparent
discrepancy between in vitro and clinical studies. Here, in a
panel of PCa cell lines, miR-221 was seen to be reduced
across a panel of prostate cancer cell lines increasing in
grade, agreeing with clinical data. However, for the highly
aggressive PC3 cell line, miR-221 expression was much
higher and its deletion from the genome caused reduction in
cell growth, an inhibition or change in cell adhesion, and a
reversal of several EMT markers. This would indicate that
miR-221 has a very complex role in PCa. MiR-221 may
mediate changes in cell-cell adhesion which may influence
cancer cells dissociating from the primary tumour mass or
influence metastatic cell adhesion to a distant site. 
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